[Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases]

Nihon Hinyokika Gakkai Zasshi. 2003 May;94(4):521-4. doi: 10.5980/jpnjurol1989.94.521.
[Article in Japanese]

Abstract

Prostatic neuroendocrine (NE) carcinoma is a rare situation and the NE differentiation in the prostate adenocarcinoma appears to be characterized as poor prognosis, rapid tumor progression and the androgen-independent state, for which there is currently no successful therapy. We report two cases of NE differentiated prostatic carcinoma, which were diagnosed adenocarcinoma initially and the tumors progressed universally with NE differentiation during androgen suppression therapy.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology*
  • Aged
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Carcinoma, Neuroendocrine / pathology*
  • Cell Differentiation
  • Disease Progression
  • Flutamide / administration & dosage
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology*

Substances

  • Antineoplastic Agents, Hormonal
  • Gonadotropin-Releasing Hormone
  • Flutamide